Regeneron, Sanofi, UnitedHealth Group sales and marketing update

Regeneron and Sanofi said UnitedHealth granted hypercholesterolemia drug Praluent alirocumab preferred status across its formularies. Praluent is a PCSK9 inhibitor. ...